Copyright
©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2010; 16(35): 4467-4475
Published online Sep 21, 2010. doi: 10.3748/wjg.v16.i35.4467
Published online Sep 21, 2010. doi: 10.3748/wjg.v16.i35.4467
Table 1 Demographic, clinical, laboratory, metabolic and instrumental features of 224 hepatocellular carcinoma patients n (%)
Variable | HCC patients (n = 224)1 |
Mean age (yr) | 54.6 ± 10.7 |
Male sex | 190 (84.8) |
Liver cirrhosis | 122 (54.5) |
Diabetes mellitus | 27 (12.1) |
Overweight or obesitya | 95 (58.6) |
Hypertension | 59 (26.3) |
Body weight (kg) | 68.8 ± 11.0 |
Body heighta (cm) | 169.4 ± 6.4 |
Mean body mass indexa (kg/m2) | 23.9 ± 3.4 |
Systolic blood pressure (mmHg) | 128 ± 16 |
Diastolic blood pressure (mmHg) | 79 ± 9 |
Mean artery pressure (mmHg) | 95 ± 10 |
Past history of HBV infection | 173 (77.2) |
Smoking | 99 (44.2) |
Alcohol intake | 69 (30.8) |
Positive for HBeAgb | 52 (26.1) |
HBV-DNAc, Log10 | 5.32 ± 1.40 |
AFPd, > 400 ng/mL | 110 (50.9) |
Child-Pugh Score2 | 6 (5-8) |
Blood Glucose (mmol/L) | 5.88 ± 2.22 |
Total Bilirubin2 (mg/L) | 13 (8-23) |
Albumin level (g/L) | 36.6 ± 6.3 |
International normalized ratio | 1.22 ± 0.24 |
Alanine aminotransferase2 (U/L) | 53 (34-83) |
γ-glutamyl transferase2 (U/L) | 113 (58-254) |
Platelet count2 (× 109/L) | 125 (81-183) |
Triglyceridese (mmol/L) | 1.02 ± 0.52 |
Total cholesterole (mmol/L) | 4.27 ± 1.33 |
HDL cholesterolf (mmol/L) | 0.93 ± 0.44 |
LDL cholesterolf (mmol/L) | 2.44 ± 1.06 |
Creatinine2 (mg/dL) | 0.9 (0.8-1.0) |
Blood urea nitrogen2 (mmol/L) | 4.98 (3.92-6.28) |
Table 2 Comparison of clinical classification, clinical stage and tumor nodus metastasis stage of hepatocellular carcinoma patients with cirrhosis (n = 122) and patients without cirrhosis (n = 102) n (%)
Total patients (n = 224) | Patients with LC (n = 122) | Patients without LC (n = 102) | P value1 | |
Clinical classification | ||||
Massive-type | 134 (59.8) | 52 (42.6) | 82 (80.4) | < 0.001 |
Nodular-type | 61 (27.2) | 49 (40.2) | 12 (11.8) | < 0.001 |
Small-type | 15 (6.7) | 13 (10.7) | 2 (2.0) | 0.010 |
Diffuse-type | 14 (6.3) | 8 (6.6) | 6 (5.9) | 0.835 |
Clinical Stage | ||||
Stage I | 15 (6.7) | 9 (7.4) | 6 (5.9) | 0.656 |
Stage II | 95 (42.4) | 44 (36.1) | 51 (50.0) | 0.036 |
Stage III | 114 (50.9) | 69 (56.6) | 45 (44.1) | 0.064 |
TNM stage | ||||
Stage I | 11 (4.9) | 8 (6.6) | 3 (2.9) | 0.212 |
Stage II | 43 (19.2) | 34 (27.9) | 9 (8.8) | < 0.001 |
Stage III | 76 (33.9) | 30 (24.6) | 46 (45.1) | 0.001 |
Stage IV | 94 (42.0) | 50 (41.0) | 44 (43.1) | 0.745 |
T Stage | ||||
Stage 1-2 | 81 (36.2) | 61 (50.0) | 20 (19.6) | < 0.001 |
Stage 3-4 | 143 (63.8) | 61 (50.0) | 82 (80.4) | - |
N Stage | ||||
Stage 0 | 194 (86.6) | 110 (90.2) | 84 (82.4) | 0.087 |
Stage 1 | 30 (13.4) | 12 (9.8) | 18 (17.6) | - |
M stage | ||||
Stage 0 | 130 (58.0) | 72 (59.0) | 58 (56.9) | 0.745 |
Stage 1 | 94 (42.0) | 50 (41.0) | 44 (43.1) | - |
Table 3 Univariate analysis of factors associated with hepatocellular carcinoma and cirrhosis n (%)
Variable | Patients with LC1 (n = 122) | Patients without LC1 (n = 102) | P value2 |
Mean age (yr) | 54.7 ± 10.0 | 54.6 ± 11.4 | 0.909 |
Male sex | 106 (86.9) | 84 (82.4) | 0.346 |
Diabetes mellitus | 19 (15.6) | 8 (7.8) | 0.077 |
Overweight or obesitya | 54 (60.7) | 41 (56.2) | 0.562 |
Hypertension | 33 (27.0) | 26 (25.5) | 0.792 |
Body weight (kg) | 69.7 ± 11.4 | 67.7 ± 10.4 | 0.168 |
Body heighta (cm) | 169.4 ± 6.2 | 169.5 ± 6.6 | 0.912 |
Mean body mass indexa (kg/m2) | 24.1 ± 3.6 | 23.7 ± 3.1 | 0.441 |
Systolic blood pressure (mmHg) | 128 ± 15 | 130 ± 16 | 0.323 |
Diastolic blood pressure (mmHg) | 78 ± 9 | 79 ± 9 | 0.255 |
Mean artery pressure (mmHg) | 95 ± 10 | 96 ± 10 | 0.243 |
Past history of HBV infection | 103 (84.4) | 70 (68.6) | 0.005 |
Smoking | 57 (46.7) | 42 (41.2) | 0.405 |
Alcohol intake | 43 (35.2) | 26 (25.5) | 0.115 |
Positive for HBeAgb | 32 (29.4) | 20 (22.2) | 0.254 |
HBV-DNAc, Log10 | 5.35 ± 1.37 | 5.26 ± 1.51 | 0.829 |
AFPd, > 400 ng/mL | 59 (50.9) | 51 (51.0) | 0.984 |
Child-Pugh Score3 | 7 (6-10) | 5 (5-6) | < 0.001 |
Blood glucose (mmol/L) | 5.99 ± 2.44 | 5.73 ± 1.93 | 0.362 |
Total bilirubin3 (mg/L) | 17 (9-31) | 10 (8-17) | < 0.001 |
Albumin level (g/L) | 34.8 ± 6.3 | 38.8 ± 5.6 | < 0.001 |
International normalized ratio | 1.31 ± 0.27 | 1.12 ± 0.15 | < 0.001 |
Alanine aminotransferase3 (U/L) | 58 (37-90) | 45 (30-81) | 0.050 |
γ glutamyl transferase3 (U/L) | 110 (52-257) | 117 (61-257) | 0.816 |
Platelet count3 (× 109/L) | 94 (61-152) | 162 (115-217) | < 0.001 |
Triglyceridese (mmol/L) | 1.02 ± 0.54 | 1.02 ± 0.49 | 0.995 |
Total cholesterole (mmol/L) | 4.08 ± 1.44 | 4.53 ± 1.13 | 0.047 |
HDL cholesterolf (mmol/L) | 0.89 ± 0.48 | 0.99 ± 0.38 | 0.152 |
LDL cholesterolf (mmol/L) | 2.21 ± 1.10 | 2.78 ± 0.92 | 0.002 |
Creatinine3 (mg/dL) | 0.9 (0.8-1.0) | 0.9 (0.8-1.0) | 0.839 |
Blood urea nitrogen3 (mmol/L) | 4.95 (3.85-6.32) | 5.02 (3.96-6.19) | 0.927 |
Table 4 Multivariate analysis of factors associated with hepatocellular carcinoma and cirrhosis
Variable1 | Adjusted OR | 95% CI | P value |
Diabetes mellitus | 4.88 | 1.08-21.99 | 0.039 |
INR | 117.14 | 4.19-3272.28 | 0.005 |
Albumin level | 0.89 | 0.80-0.99 | 0.027 |
Platelet count | 0.992 | 0.987-0.997 | 0.002 |
- Citation: Gao C, Zhao HC, Li JT, Yao SK. Diabetes mellitus and hepatocellular carcinoma: Comparison of Chinese patients with and without HBV-related cirrhosis. World J Gastroenterol 2010; 16(35): 4467-4475
- URL: https://www.wjgnet.com/1007-9327/full/v16/i35/4467.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i35.4467